Recurrent Uti Clinical Trial
Official title:
A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections
Patients with recurrent UTI were randomized to receive either the probiotic Sacchromyces Boulardii at enrollment, and the intracellularly active Ciprofloxacin with their first UTI episode after enrollment, or they received standard of care treatment.
- At the time of consent, participants will be given 20 mg/kg of the antibiotic, ciprofloxacin. If the participant has symptoms of a UTI or have a positive urine culture at enrollment, they will take the antibiotic every 12 hours for 14 days. If the participant does not have symptoms of a UTI at enrollment, the antibiotic will be taken only if needed at home upon the first occurrence of a UTI. - At the time of consent, participants will also be given 250 mg of the probiotic, S. boulardii, taken once daily for 6 months, irrespective of symptoms. - Throughout the study, participants will receive their standard clinical care for recurrent UTI treatment, which includes bowel and bladder dysfunction management and other prescribed non-antibiotic interventions at the managing provider's clinical discretion. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04096820 -
Uromune in Treating Recurrent Urinary Tract Infections in Women
|
Phase 2 | |
| Completed |
NCT03210038 -
Cystoscopy in Females: Is There a Difference Between Rigid and Flex Cystoscopy, and Does it Require Local Anasthesia?
|
N/A | |
| Completed |
NCT03644966 -
Probiotics and Multi-Drug Resistant Urinary Tract Infection
|
N/A | |
| Not yet recruiting |
NCT06332781 -
Intravesical Gentamicin to Prevent Recurrent UTI
|
Phase 4 |